Sotirimod
Based on 1 Customer Validation
Sotirimod (R850) is a TLR7 agonist and immunomodulator. Sotirimod inhibits Apoptosis. Sotirimod is applicable to research related to actinic keratosis, early cervical HPV infection, and precancerous lesions of colorectal cancer.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.90%
- CAS No.: 227318-75-4
- 화학식: C14H17N5
- 분자량:255.32
-
보관:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
Biological Activity
|
TLR7 |
Chemical Information
-
CAS No. 227318-75-4
-
Appearance Solid
-
분자량 255.32
-
화학식 C14H17N5
-
Color White to off-white
-
SMILES
NC1=NC2=CC=CN=C2C3=C1N=C(C)N3CC(C)C
-
Synonyms
R850
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
용액&용해도
DMSO : 25 mg/mL (97.92 mM; ultrasonic and warming and heat to 80°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (9.79 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (279 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.9167 mL | 19.5833 mL | 39.1665 mL | 97.9163 mL |
| 5 mM | 0.7833 mL | 3.9167 mL | 7.8333 mL | 19.5833 mL | |
| 10 mM | 0.3917 mL | 1.9583 mL | 3.9167 mL | 9.7916 mL | |
| 15 mM | 0.2611 mL | 1.3056 mL | 2.6111 mL | 6.5278 mL | |
| 20 mM | 0.1958 mL | 0.9792 mL | 1.9583 mL | 4.8958 mL | |
| 25 mM | 0.1567 mL | 0.7833 mL | 1.5667 mL | 3.9167 mL | |
| 30 mM | 0.1306 mL | 0.6528 mL | 1.3056 mL | 3.2639 mL | |
| 40 mM | 0.0979 mL | 0.4896 mL | 0.9792 mL | 2.4479 mL | |
| 50 mM | 0.0783 mL | 0.3917 mL | 0.7833 mL | 1.9583 mL | |
| 60 mM | 0.0653 mL | 0.3264 mL | 0.6528 mL | 1.6319 mL | |
| 80 mM | 0.0490 mL | 0.2448 mL | 0.4896 mL | 1.2240 mL |
Sotirimod Related Classifications
HY-101589 Related Classifications
Powered by Bioz
- Sotirimod
- 227318-75-4
- R850
- R 850
- R-850
- Toll-like Receptor (TLR)
- Apoptosis
- gastrointestinal epithelial cells
- TLR7
- actinic keratoses
- colorectal polyps/polyposis
- precancerous colorectal changes
- early cervical HPV infections
- precancerous gastrointestinal cells
- colorectal cancer
- malignant colorectal tumour cells
- Inhibitor
- inhibitor
- inhibit